在接受empagliflozin治疗的患者中,左心室质量预测心脏逆转重塑
Pankaj Puar1,2,3,4, Makoto Hibino5, C David Mazer2,3,6,7,8
1Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, 30 Bond Street, Toronto, ON, Canada.
Cardiovascular diabetology
|June 28, 2023
概括
用empagliflozin抑制-葡萄糖共运输体-2可促进心脏逆向重塑. 具有较高基线左心室质量指数的患者经历了更大的益处,这表明个性化治疗的潜力.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- SGLT2 抑制剂对心血管的益处部分归因于心脏逆向重塑.
- 在EMPA-HEART CardioLink-6研究中,empagliflozin在左心室质量指数 (LVMi) 中显著降低.
- 本次分分析调查了基线LVMi对empagliflozin对心脏逆转重塑的影响.
研究的目的:
- 评估基线左心室质量指数 (LVMi) 对心脏逆向重塑的影响.
- 为了确定empagliflozin对LVMi的影响是否基于初始LVMi水平而有所不同.
- 探索SGLT2抑制剂治疗的个性化治疗策略.
主要方法:
- 97名2型糖尿病和冠状动脉疾病患者被随机分配给empagliflozin或安慰剂6个月.
- 根据基线LVMi,患者被分为两组:≤60g/m2和>60g/m2.
- 小组分析使用ANCOVA与相互作用术语来比较治疗组之间的LVMi变化.
主要成果:
- 基线LVMi>60g/m2的患者显示,使用empagliflozin的LVMi显著降低 (-7.26g/m2,p=0.0011).
- 在基线LVMi≤60g/m2 (-0.46g/m2,p=0.76) 的患者中没有观察到显著的LVMi降低.
- 根据基线LVMi,对于LV体积或喷射分数的变化没有发现显著的相互作用.
结论:
- 较高的基线左心室质量指数预测左心室质量的较大回归与empagliflozin治疗.
- 恩帕格利弗洛辛有效诱导心脏反向重塑,特别是在患有高LVMi的患者中.
- 基线LVMi是预测使用empagliflozin实现的心脏逆转改造程度的关键因素.
相关概念视频
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
17
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17